How will Medicare and drug companies effectively negotiate on matters of price? What are the real deficiencies in how drugs get to the people who need them? Michael Cannon comments.
Setting the Table for Medicare’s Drug Price Negotiations
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.